[HTML][HTML] Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
A Casal-Mouriño, A Ruano-Ravina… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of
patients with differences in the extent and localization of disease. Many aspects of stage III …
patients with differences in the extent and localization of disease. Many aspects of stage III …
Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice
Background Carboplatin is the backbone cytotoxic agent for many chemotherapy regimens
for lung cancer. Dosing of carboplatin is complicated due to its relationship to renal function …
for lung cancer. Dosing of carboplatin is complicated due to its relationship to renal function …
GRADE-ADOLOPMENT of clinical practice guidelines and creation of clinical pathways for the primary care management of chronic respiratory conditions in Pakistan
RS Martins, H Hussain, M Chaudry, NA Rizvi… - BMC Pulmonary …, 2023 - Springer
Abstract Introduction In Pakistan, chronic respiratory conditions contribute a large burden of
morbidity and mortality. A major reason for this is the lack of availability of local evidence …
morbidity and mortality. A major reason for this is the lack of availability of local evidence …
Influence of timeliness and receipt of first treatment on geographic variation in non‐small cell lung cancer mortality
Mortality from non‐small cell lung cancer (NSCLC) exhibits substantial geographical
disparities. However, there is little evidence on whether this variation could be attributed to …
disparities. However, there is little evidence on whether this variation could be attributed to …
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists
U Nindra, V Bray, D Karikios, M Shafiei… - Oncology, 2024 - karger.com
Abstract Introduction: Local Australian guidelines for the optimal management of stage III
unresectable non-small cell lung cancer (NSCLC) are lacking. The American Society of …
unresectable non-small cell lung cancer (NSCLC) are lacking. The American Society of …